Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432F. Wang, Rui‐Hua Xu, Fenggong Wang et al.|Annals of Oncology|2019Cited by 475
Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathwayXiang Hu, San-Jun Cai|Journal of Experimental & Clinical Cancer Research|2018Cited by 79